Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 1, 2008, Pages 306-312

  Tudhope, Susan J ^a   Finney Hayward, Tricia K ^a   Nicholson, Andrew G ^b   Mayer, Ruth J ^c   Barnette, Mary S ^c   Barnes, Peter J ^a   Donnelly, Louise E ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 27; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N CYANO N' [2 [[8 (2,6 DIFLUOROPHENYL) 4 (4 FLUORO 2 METHYLPHENYL) 7 OXO 7,8 DIHYDROPYRIDO[2,3 D]PYRIMIDIN 2 YL]AMINO]ETHYL]GUANIDINE; PROTEIN P42; PROTEIN P44; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; CELL LINEAGE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; SPUTUM;

CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; FLAVONOIDS; HUMANS; LIPOPOLYSACCHARIDES; LUNG; MACROPHAGES; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES;

EID: 37349096435     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.127670     Document Type: Article

References (26)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, and Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489-27494.
2. Bain J, McLauchlan H, Elliott M, and Cohen P (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371:199-204.
3. Barnes PJ (2004a) Alveolar macrophages as orchestrators of COPD. COPD 1:59-70.
4. Barnes PJ (2004b) Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 56:515-548.
5. Barnes PJ (2006) Corticosteroids: the drugs to beat. Eur J Pharmacol 533:2-14.
6. Boehm JC and Taggart JJ (2006) inventor; GlaxoSmithKline, assignee. Novel compounds. U.S. patent application 20060217401. 2006 Sept 28.
7. Carter AB, Monick MM, and Hunninghake GW (1999) Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 20:751-758.
8. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
9. Fujimoto K, Yamaguchi S, Urushibata K, Hanaoka M, Koizumi T, Honda T, and Kubo K (2006) Characteristics of asthma resistant to moderate dose inhaled corticosteroid treatment on bronchial hyperresponsiveness. Intern Med 45:843-849.
10. Gantner F, Kupferschmidt R, Schudt C, Wendel A, and Hatzelmann A (1997) In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 121:221-231.
11. Haddad EB, Birrell M, McCluskie K, Ling A, Webber SE, Foster ML, and Belvisi MG (2001) Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol 132:1715-1724.
12. Johnson GL and Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912.
13. Koch A, Giembycz M, Stirling RG, Lim S, Adcock I, Wassermann K, Erdmann E, and Chung KF (2004) Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages. Eur Respir J 23:805-812.
14. Kumar S, Boehm J, and Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2:717-726.
15. Mealy NE and Bayes M (2005) Treatment of respiratory disorders. Drugs Future 30:51-112.
16. Meja KK, Seldon PM, Nasuhara Y, Ito K, Barnes PJ, Lindsay MA, and Giembycz MA (2000) p38 MAP kinase and MKK1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism. Br J Pharmacol 131:1143-1153.
17. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, Mellor GW, Evans C, and Roshak AK (2005) Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3- thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 312:373-381.
18. Seldon PM, Barnes PJ, Meja K, and Giembycz MA (1995) Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 48:747-757.
19. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, and Giembycz MA (2004) Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66:1679-1689.
20. Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, Higgins LS, Giembycz MA, Barnes PJ, and Donnelly LE (2006) Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 149:393-404.
21. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, Wendel A, Church MK, and Shute JK (1995) Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 25:625-633.
22. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, et al. (2000) SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. Crit Care Med 293:281-288.
23. Wang B, Cleary PP, Xu H, and Li JD (2003) Up-regulation of interleukin-8 by novel small cytoplasmic molecules of nontypeable Haemophilus influenzae via p38 and extracellular signal-regulated kinase pathways. Infect Immun 71:5523-5530.
24. Westra J, Limburg PC, de Boer P, and van Rijswijk MH (2004) Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 63:1453-1459.
25. Young DA, Lowe LD, and Clark SC (1990) Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colonystimulating factor in supporting monocyte differentiation in culture: analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 145:607-615.
26. Zhang X, Msc, Moilanen E, Lahti A, Hamalainen M, Giembycz MA, Barnes PJ, Lindsay MA, and Kankaanranta H (2003) Regulation of eosinophil apoptosis by nitric oxide: role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5. J Allergy Clin Immunol 112:93-101.